Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.
Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer.
Proof Diagnostics develops CRISPR‑based COVID‑19 molecular tests to help communities take control of their health.
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Excision BioTherapeutics Inc. is a life science company founded in 2015 and based in Philadelphia, Pennsylvania, dedicated to developing gene editing therapeutics for life-threatening diseases caused by neurotropic viruses. The company utilizes CRISPR-based technology to create advanced gene-editing medicines aimed at eradicating or disrupting viral genes in patients. By focusing on addressing the medical needs associated with viral infections, Excision aims to advance safe and effective therapeutics that can significantly enhance the quality of life for individuals affected by these diseases globally.
Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. This innovative approach seeks to reverse diseases and transform medical practices. The company brings together a diverse community of leading scientists, clinicians, and industry experts who collaborate to advance this mission. Altos Labs operates in the San Francisco Bay Area and San Diego, as well as in Cambridge, UK, and maintains significant research collaborations in Japan.
SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Walden Biosciences, Inc, a biotechnology company, develops medicines for individuals living with kidney disease. It targets suPAR, an inflammatory biomarker that connects the kidney to the innate immune system; and Dynamin, a complex enzyme that rebuilds podocytes and the base structure of the kidney. The company was incorporated in 2013 and is based in Cambridge, Massachusetts.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid (HOCl) products for various healthcare applications, including wound care, animal health, eye care, oral care, and dermatological conditions. The company offers a range of products such as Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription treatment for dermatoses; and Celacyn gel, which promotes healing of scars from surgical procedures and trauma. Additional offerings include SebuDerm for seborrhea management, Ceramax as a skin barrier cream, and Acuicyn for eye-related inflammation and cleanliness. Sonoma's Microcyn product line targets expedited healing of wounds and includes solutions for both human and animal care, addressing conditions such as hot spots and skin irritations. With over 100 commercialized products in 33 countries, Sonoma Pharmaceuticals aims to meet unmet medical needs while enhancing patient care and reducing healthcare costs. The company, originally known as Oculus Innovative Sciences, Inc., was rebranded in December 2016 and is headquartered in Woodstock, Georgia.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.
Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.
The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
Elpis Biomed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.
CERo Therapeutics, Inc., a biotechnology company, researches and develops platforms for cellular immunotherapy. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Vizgen, Inc. is a biotechnology company focused on developing advanced spatially resolved transcriptomic profiling tools to enhance understanding of biological systems related to human health and disease. Its flagship technology, MERFISH, is a patented multiplexed single-molecule imaging method that allows for the simultaneous measurement of RNA species' copy number and spatial distribution within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various diseases and biological processes. The applications of Vizgen's technology span several fields, including oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen aims to support tissue-scale research and development, contributing to the discovery and mapping of diverse cell types and states across multiple tissues and organisms.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Epirium Bio, Inc. develops compounds for treatment of cardiovascular diseases and metabolic syndrome. Epirium Bio, Inc. was formerly known as Cardero Therapeutics, Inc. The company was incorporated in 2008 and is based in San Diego, California.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.
Agrivida, Inc. is an agricultural biotechnology company that specializes in developing feed additives and renewable biomass-based alternative fuels. Founded in 2002 and based in Cambridge, Massachusetts, Agrivida focuses on nutritional solutions for a variety of livestock, including poultry, swine, dairy and beef cattle, and aquaculture. The company offers products such as GRAINZYME, a phytase feed additive for poultry, and INzyme Enzymes, which provide regulated enzymes for various applications including detergents and food production. In addition, Agrivida develops corn varieties optimized for producing ethanol from corn stover, contributing to the production of clean-burning, renewable fuels.
One BioMed Pte. Ltd. is a Singapore-based company that specializes in integrated molecular diagnostics services. Established in 2015, it focuses on delivering advanced medical diagnostic solutions to enhance patient care. The company's offerings aim to improve the accuracy and efficiency of disease detection and monitoring, contributing to better health outcomes. Through its innovative approaches, One BioMed is positioned to play a significant role in the evolving landscape of medical diagnostics.
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer.
It was founded in 2018 and headquartered in San Diego, California.
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.
HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.
Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.
Glympse Bio, Inc. is focused on developing modular nanoparticle sensors for diagnostics in fibrosis, cancer, immunology, and infectious diseases, as well as for monitoring drug response. The company utilizes engineered diagnostic agents that assess disease states within the body and convey this information to urine for analysis. Its flagship product, Glympse Inside, serves as a pan-disease engine intended to enhance disease monitoring and treatment response. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's innovative platform technology originated at MIT and is backed by a team of experts in nanomedicine and biomedical engineering.
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.
Karuna Pharmaceuticals, Inc. engages in development of drugs for the treatment of schizophrenia. The company was incorporated in 2009 and is based in Boston, Massachusetts.
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.
Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform. Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.
Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, focused on developing innovative therapies primarily in immunology and dermatology. The company is advancing several product candidates, including SNA-120, a first-in-class inhibitor targeting tropomyosin receptor kinase A, currently in a Phase IIb trial for psoriasis and related pruritus. Another candidate, SNA-125, is a topical dual Janus kinase 3 inhibitor undergoing Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is developing SNA-001, a topical suspension of silver particles, which is in pivotal trials for treating acne and reducing the appearance of light-pigmented hair. Sienna Biopharmaceuticals was founded in 2010 as Sienna Labs, Inc. and changed its name in 2016. The company faced financial challenges, filing for Chapter 11 bankruptcy in September 2019, which later converted to Chapter 7.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, focused on developing innovative therapies primarily in immunology and dermatology. The company is advancing several product candidates, including SNA-120, a first-in-class inhibitor targeting tropomyosin receptor kinase A, currently in a Phase IIb trial for psoriasis and related pruritus. Another candidate, SNA-125, is a topical dual Janus kinase 3 inhibitor undergoing Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is developing SNA-001, a topical suspension of silver particles, which is in pivotal trials for treating acne and reducing the appearance of light-pigmented hair. Sienna Biopharmaceuticals was founded in 2010 as Sienna Labs, Inc. and changed its name in 2016. The company faced financial challenges, filing for Chapter 11 bankruptcy in September 2019, which later converted to Chapter 7.
Aira Tech Corp. is dedicated to enhancing accessibility for blind and low-vision individuals through its innovative online platform, which acts as a visual interpreter and navigator. The service connects users with trained agents, family members, or friends for remote assistance, utilizing smart glasses linked to the user’s smartphone. By simply downloading the app and activating the camera, users can stream live video to highly screened visual interpreters who provide real-time guidance and support. Founded in 2015 and headquartered in La Jolla, California, Aira aims to make the world more accessible, ensuring that individuals can navigate their environments with greater independence and confidence. The platform has been recognized for its significant impact, being described as a "Godsend" by The New York Times.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources to address significant health challenges, particularly resistant infectious diseases and cancers. Founded to advance the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo utilizes a genome-based, culture-independent platform to discover and characterize small molecules from microbial sources found in soil. By leveraging advancements in DNA sequencing and bioinformatics, the company aims to unlock the therapeutic potential of previously undiscovered molecules encoded in microbial DNA, with a focus on treating conditions that have high unmet medical needs. Lodo Therapeutics, supported by Accelerator Corporation, is headquartered in New York City, where its laboratory and offices are located within the Alexandria Center for Life Science.
Petra Pharma Corporation, a pharmaceutical company, discovers and develops therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and other serious diseases. It focuses on novel enzyme targets that play a central role in various important cellular processes, including cell division, growth, trafficking, and signaling. The company was incorporated in 2015 and is based in New York, New York.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.
Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.
Voxel8 Inc. designs and manufactures electronic devices. It offers desktop 3D printers that are used to print thermoplastics or UV resins. The company also provides Project Wire, a cloud software tool that is used for designing 3D printable electronic devices that can be rapidly fabricated using the Voxel8 3D printer. Voxel8 Inc. was incorporated in 2013 and is based in Somerville, Massachusetts.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.
Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age related changes in skin.
Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts.
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.
Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).
Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell-based cancer immunotherapies using chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically modify T cells to target and eliminate cancer cells. The company is advancing a diverse pipeline of product candidates, including JCAR017 and JCAR014 for relapsed or refractory B cell malignancies, and JCAR018 for pediatric patients with CD22-positive cancers. Additional candidates include therapies targeting neuroblastoma, lung cancer, ovarian cancers, and glioblastoma, among others. Juno Therapeutics collaborates with prominent cancer research institutions such as Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center to enhance its research and development efforts. Founded in 2013 and headquartered in Seattle, Washington, Juno Therapeutics has established itself as a leader in immunotherapy innovation and operates as a subsidiary of Bristol-Myers Squibb Company.
WuXi NextCODE is a clinical diagnostics company focused on genomics, providing a platform that helps physicians derive clinical insights for rapid patient diagnoses. The company specializes in genome interpretation, data analysis, and data mining services, alongside offering security and data protection solutions. It also provides custom integration services and both clinical-grade and non-clinical-grade sequencing services. Originating from technology developed at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care. Based in Cambridge, Massachusetts, the company became a subsidiary of WuXi PharmaTech in 2015 and was rebranded as Genuity Science in 2020.
Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing innovative biological products for the agriculture industry. Founded in 2012, AgBiome utilizes advanced genomics and screening technologies to identify plant-associated microbes that enhance plant health, pest resistance, and crop yields. The company manufactures fungicides to protect crops from soil-borne and foliar diseases while also employing a platform that captures and screens diverse microbes for their effectiveness against insects, diseases, and nematodes. AgBiome collaborates with leading agricultural firms to accelerate its discovery process and deliver solutions that address critical challenges in global food production. With a workforce of approximately 87 employees and a state-of-the-art laboratory and greenhouse facility in the Research Triangle Park, AgBiome aims to provide sustainable and effective solutions for farmers facing significant agricultural issues.
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis globally, including the United States, China, Japan, and Europe. Founded in 2012 and headquartered in Boston, Massachusetts, the company utilizes mass spectrometry technology to create handheld and desktop devices suitable for various applications in life sciences research, bioprocessing, industrial biotech, and forensics. Notable products include the MX908, a portable, battery-operated mass spectrometry device designed for the rapid analysis of unknown materials in various states; the Rebel, a desktop analyzer that provides real-time data on bioprocess environments; and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. 908 Devices aims to make the capabilities of mass spectrometry accessible beyond traditional laboratories, offering rugged and reliable tools for immediate field use.
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.
Cooledge Lighting is a venture backed start-up focused on delivering high value solid-state lighting solutions to the general illumination market. Founded in 2009, Cooledge is currently in the development stage of the company with product launch coming at Lightfair 2013 in Philadelphia, PA.
Newvem is the leader in enhancing cloud usage effectiveness through data analytics. Newvem’s KnowYourCloud Analytics, a free SaaS solution for Amazon AWS customers, provides a 360-degree view of their cloud usage to enable running a reliable and efficient cloud deployment. The service collects and analyzes AWS usage data, revealing issues and anomalies in their cloud, and recommends actionable insights that help solve not just cost efficiency, but security, availability and utilization issues as well. Dev-Ops, IT Managers and Business Managers use Newvem everyday to discover meaningful insights on their cloud-based infrastructure, including potential costs savings, security threats, and availability issues. Newvem is led by a seasoned team of serial entrepreneurs and is funded by Greylock Partners, Index Ventures, Innovation Endeavors and others.